Engineered cells take on tough blood cancer in first human trial
Disease control
Recruiting now
This early-phase study tests a new treatment called OC-1, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack a specific marker (CD1a) on cancer cells. The trial aims to see if this therapy is safe and can help shrink or elim…
Phase: PHASE1 • Sponsor: OneChain Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC